Document:

EX-4.1.1

 Exhibit 4.1.1 

CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY
DISCLOSED. SUCH EXCLUDED INFORMATION HAS BEEN MARKED WITH “[***]”. 
 UNIVERSITY OF
MINNESOTA 
 FIRST AMENDMENT TO THE EXCLUSIVE PATENT LICENSE AGREEMENT 

THIS FIRST AMENDMENT TO THE EXCLUSIVE PATENT LICENSE AGREEMENT (the “First Amendment”) is entered into as of the date of last
signature by and between the Regents of the University of Minnesota, a Minnesota constitutional corporation under the laws of the state of Minnesota, having a place of business at 1000 Westgate Drive, Suite 160, St. Paul, MN 55114 (the
“University”), and Cellectis S.A., a corporation under the laws of the country of France having a business address of 8, rue de la Croix Jarry, 75013, Paris, France (the “Licensee” or “Cellectis S.A.”). 

The University and the Licensee are individually referred to herein as a “Party” or collectively as the “Parties”. 

BACKGROUND 
 University
and Licensee entered into an Exclusive Patent License Agreement, dated and effective as of 10 January 2011, (the “License Agreement”), which incorporated the Terms and Conditions as defined in the License Agreement under which
University granted to Licensee an exclusive license to University’s rights in the Licensed Technology, as defined in the License Agreement. 

The Parties now wish to amend and clarify the Licensees’ rights and obligations under the License Agreement. 

NOW, THEREFORE, the Parties agree as follows: 
  

	1.	 Definitions. 

Capitalized terms used in this First Amendment that are not otherwise defined herein shall have the meanings ascribed to them in the Agreement. 

 

	2.	 Amendments to the Agreement. Effective the First Amendment Effective Date, the Parties hereby agree to
amend the License Agreement as follows: 

 2.1 Licensee. Section 1 of the EPLA is hereby amended to add the
following provision: 
 “For any avoidance of doubt, an Affiliate of Cellectis S.A. shall not be considered a Third Party.” 

2.2 Definitions. The Terms and Conditions are hereby amended to add the following provisions as sections 1.19, 1.20 and 1.21: 

“1.19 TALEN(s)’ shall mean a Licensed Product that is an endonuclease whose DNA recognition domain is composed of DNA binding domains
derived from transcription activator-like (TAL) effectors protein. 
 “1.20 [***] 

“1.21 Cellectis Bioresearch’ shall mean Cellectis Bioresearch SAS, which is an Affiliate of Cellectis S.A.” 

 2.3 Sublicense Revenues. Section 1.14 of the Terms and Conditions are hereby
deleted in its entirety and the following substituted in its stead: 
 “‘Sublicense Revenues’ means [***] 

2.4 Running Royalties. The EPLA is hereby amended to add the following provision to subsection 11.4.1: 

“For the avoidance of doubt, the Parties acknowledge and agree that sublicenses granted by the Licensee to a Third Party solely as part of
the Third Party’s purchase of TALEN(s) from Licensee shall be reported as Commercial Sales of Licensed Products under this subsection 11.4.1 on which a [***] royalty as provided in this subsection shall be due. 

“For further clarity, for sublicenses granting the Third Party both a license (i) to use Licensed Products for such persons’
commercial or other lawful purposes as part of a purchase of the Licensed Products and (ii) to practice the Licensed Technology to make and use TALEN(s), the Licensee shall clearly and reasonably specify in the sublicense agreement which
payments are linked to the purchase of Licensed Products and which to the right to practice the Licensed Technology to make and use TALEN(s).” 

“For additional clarity, such [***] royalty is due on i) the sale of Licensed Products by Licensee (for example, when Licensee sells a
TALEN, or a cells modified with the TALENs); or ii) the sublicense fee associated with sales of Licensed Products (for example, when Licensee sells a TALEN and grants the right to use the TALEN to develop cells).” 

2.5 Payments. Section 11.5 of the EPLA is hereby deleted in its entirety and the following substituted in its stead: 

“As determined and payable as provided in section 6.4 of the Terms and Conditions, the licensee shall pay to the University [***] of all
Sublicense Revenues paid to the Licensee in a calendar quarter during the Term and the Post-termination Period within thirty (30) days after the last day of such quarter. Notwithstanding any provision of this Agreement to the contrary, the
Licensee shall have no obligation to pay the University any amount under this section 11.5 for moneys paid by Third Parties to 
 the
Licensee in connection with the Licensee granting such persons a right to use Licensed Products for their commercial or other lawful purposes as part of a purchase of Licensed Products.” 

2.6 Financial Compensation. The EPLA is hereby amended to add the following provision as section 11.11: 

“1.1.11 In addition to amounts owed by the Licensee to the University under other sections of this Agreement, the Licensee shall pay the
University the following sums: 
 (i) within sixty (60) days after the final day of each calendar quarter during the Term and the
Post-termination Period, [***] of all moneys actually paid to Cellectis Bioresearch under [***]; provided, however, the Licensee shall have no obligation under this part (i) of section 11.11 to make such payments for moneys earned after the
third (3rd) anniversary of the effective date of [***]; 

  
 - 1 - 

 (ii) within thirty (30) days after the actual receipt by Cellectis Bioresearch of the
milestone payment for having obtained cumulative Net Revenues of at least [***], as provided in [***]; and 
 (iii) within thirty
(30) days after the actual receipt by Cellectis Bioresearch of the milestone payment for having obtained cumulative Net Revenues of [***].” 

2.7 Patent Application Filings during the Term. The Terms and Conditions are hereby amended to add the following provision as section
4.4: 
 “4.4 The Licensee, without having obtained the consent of the University, may seek and obtain intellectual property protection
for improvements to the Licensed Technology developed solely by the Licensee or developed jointly by the Licensee and a third party, other than an employee or student of the University working in the course of their employment or academic duties or
using University resources.” 
 2.8 Licensee’s Address. Section 12 of the EPLA is hereby deleted in its entirety and
the following substituted in its stead: 
 “Notices will be sent to the Licensee at: 

Cellectis S.A. 
 Attn.:
Mr. Andre Choulika (Chief Executive Officer) 
 8, rue de la Croix Jerry 

75013 Paris, FRANCE 
 Voice Phone
No.: +33 1 81 69 16 00 
 Facsimile No.: +33 1 81 69 16 06 

2.9 Licensee’s Contact Person for Patent Prosecution Consultation. Section 13 of the EPLA is hereby deleted in its entirety
and the following substituted in its stead: 
 “The University will, as set forth below in this Agreement, communicate with the contact
person named below with respect to patent prosecution and maintenance: 
 Cellectis S.A. 

8, rue de la Croix Jarry 
 75013
Paris, FRANCE 
 Voice Phone No.: +33 1 81 69 16 00 

Facsimile No.: +33 1 81 69 16 06 

  
 - 2 - 

 Upon ten (10) days prior written notice or email to the University, the Licensee may
change the person designated above.” 
 3. General Provisions. 

3.1 Except as amended in this First Amendment, the terms of the License Agreement remain unchanged and in full force and effect. 

3.2 The License Agreement, as amended by this First Amendment, constitutes the entire agreement between the Parties with respect to the
subject matter hereof. 
 3.3 This First Amendment may be executed in two counterparts, each of which will be deemed an original, but all of
which together shall constitute one and the same instrument. 
 IN WITNESS WHEREOF, the parties hereto have caused their duly
authorized representatives to execute this First Amendment to the Exclusive Patent License Agreement. 
  

							
	Regents of the University of Minnesota	  	Cellectis S.A.
				
	By:	 	 /s/ Jay W. Schrankler
	  	By:	 	 /s/ André Chjoulika

	Name:	 	Jay W. Schrankler	  	Name:	 	André Chjoulika
				
	Title:	 	Executive Director	  	Title:	 	Chief Executive Officer
	Office for Technology Commercialization	  		 	
				
	Date:	 	 May 24, 2012
	  	Date:	 	 May 11, 2012

  
 - 3 -EX-4.1.2

 Exhibit 4.1.2 

CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY
DISCLOSED. SUCH EXCLUDED INFORMATION HAS BEEN MARKED WITH “[***]”. 
  

	
	  

	  
 [***]

 

	  

 UNIVERSITY OF MINNESOTA 

SECOND AMENDMENT TO THE EXCLUSIVE PATENT LICENSE AGREEMENT 

THIS SECOND AMENDMENT TO THE EXCLUSIVE PATENT LICENSE AGREEMENT (the “Second Amendment”) is entered into as of the date of
last signature by and between the Regents of the University of Minnesota, a Minnesota constitutional corporation under the laws of the state of Minnesota, having a place of business at 1000 Westgate Drive, Suite 160, St. Paul, MN 55114 (the
“University”), and Cellectis S.A., a corporation under the laws of the country of France having a business address of 8, rue de la Croix Jarry, 75013, Paris, France (the “Licensee” or “Cellectis S.A.”). 

The University and the Licensee are individually referred to herein as a “Party” or collectively as the “Parties”. 

BACKGROUND 
 University
and Licensee entered into an Exclusive Patent License Agreement, dated and effective as of 10 January 2011 as amended by an Amendment 1 entered into on May 2401, 2012 (hereinafter the “Agreement”), which incorporated the Terms and
Conditions as defined in the Agreement under which University granted to Licensee an exclusive license to University’s rights in the Licensed Technology, as defined in the License Agreement. 

The Parties now wish to amend and clarify the Licensees’ rights and obligations under the Agreement. 

NOW, THEREFORE, the Parties agree as follows: 

1. Definitions. 
 Capitalized terms used
in this Second Amendment that are not otherwise defined herein shall have the meanings ascribed to them in the Agreement. 
 2. Amendments to the
Agreement. The Parties hereby agree to amend the Agreement as follows: 
 2.1 Section 3.1.2 of the Terms and Conditions is hereby
deleted in its entirety and replaced with the following: 
 “Licensee may grant sublicenses of its rights under this Agreement. Such
grant of sublicenses may include the right to grant further sublicenses (“Second-Level Sublicenses”). By way of clarification, the provisions regarding calculation of royalties for sublicenses shall apply to calculation of royalties for
Second-Level 

 Sublicenses. For sake of clarity, the basis of calculating such royalties due by Licensee
are the Commercial Sales invoiced by Licensee. Licensee shall deliver to the University true, correct and complete copies of sublicense agreements or other agreements under which the Licensee purports or intends to grant such sublicense rights
within ten (10) days after the execution of such agreements. Licensee shall deliver or cause to be delivered to the University true, correct and complete copies of Second-Level Sublicenses upon request. The Licensee shall not enter into (and
shall not permit any other party to enter into sublicense agreements) if the terms of such agreements are inconsistent in any respect with the terms of this Agreement, including without limitation, Sections 5.2 through 5.6, 6.5, 8.3, 9.5, 10.3, and
11.3. Any sublicense made in violation of this subsection is void and constitutes an event of default under subsection 
 2.2
Section 5.6.1 of the Terms and Conditions is deleted in its entirety and replaced with the following: 
 “The Licensee and any sub-licensees may mark all Licensed Products in a manner consistent with their current patent marking practices for their own products and applicable laws and regulations. Where marking is to be performed but the
Licensed Product cannot be marked, the patent notice shall be placed on associated tags, labels, packaging, or accompanying documentation either electronic or paper as appropriate.” 

2.3 The Terms and Conditions are hereby amended to add the following provision in section 8.3 of the Terms and Conditions: 

“Notwithstanding anything contained herein, in case of termination of this Agreement by the University pursuant to the terms herein, any
sublicensee (each an “Exclusive Sublicensee” as further defined hereinafter) that has been granted exclusive rights under the Licensed Technology by Licensee, within a certain field (the “Exclusive Field”), [***]. 

[***].” 
 3. General Provisions. 

3.1 Except as amended in this Second Amendment, the terms of the Agreement remain unchanged and in full force and effect. 

3.2 The Agreement, as amended by this Second Amendment, constitutes the entire agreement between the Parties with respect to the subject
matter hereof. 
 3.3 This Second Amendment may be executed in two counterparts, each of which will be deemed an original, but all of which
together shall constitute one and the same instrument. 

 IN WITNESS WHEREOF, the parties hereto have caused their duly authorized
representatives to execute this Second Amendment to the Exclusive Patent License Agreement. 
  

							
	Regents of the University of Minnesota	  	Cellectis S.A.
				
	By:	 	 /s/ Jay w. Schrankler
	  	By:	 	 /s/ André Choulika

	Name:	 	Jay W. Schrankler	  	Name:	 	André Choulika
				
	Title:	 	Executive Director	  	Title:	 	Chief Executive Officer
	Office for Technology Commercialization	  		 	
				
	Date:	 	5-27-14	  	Date:	 	01/04/14

  
 - 2 -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00318-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00318-of-00352.parquet"}]]